Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi, Geoffrey M Matthews, Victoria M Garbitt, Stephen E Palmer, Jake Shortt, Marcus Lefebure, A Keith Stewart, Ricky W Johnstone, P Leif Bergsagel
Blood | AMER SOC HEMATOLOGY | Published : 2012
Awarded by National Institutes of Health
Awarded by National Cancer Institute
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL INSTITUTE ON AGING
This work was supported by National Institutes of Health grant AG20686, National Cancer Institute grant CA136671 (P.L.B.), and by the Multiple Myeloma Research Foundation (M.C.). R.W.J. is a Principal Research Fellow of the National Health and Medical Research Council of Australia (NHMRC) and is supported by NHMRC Program and Project grants, the Susan G. Komen Breast Cancer Foundation, the Prostate Cancer Foundation of Australia, Cancer Council Victoria, The Victorian Cancer Agency, The Leukemia Foundation of Australia, Victorian Breast Cancer Research Consortium, and the Australian Rotary Health Foundation. G.M.M. is supported by an Australian Biomedical Fellowship (Peter Doherty) from the NHMRC. J.S. is supported by the Leukemia Foundation of Australia and the Cooperative Research Center for Biomedical Imaging Development. M.L. is supported by the Leukemia Foundation of Australia. The laboratory of R.W.J. receives research funding from Novartis for studies involving panobinostat.